What is OncoZenge?
OncoZenge is a Swedish pharmaceutical firm dedicated to creating advanced therapeutic solutions for managing oral pain experienced by cancer patients undergoing radiation treatment and chemotherapy. The company's focus is on improving the quality of life for individuals facing these challenging medical procedures.
How much funding has OncoZenge raised?
OncoZenge has raised a total of $3.1M across 1 funding round:
Stock/Share Issuance
$3.1M
Stock/Share Issuance (2025): $3.1M, investors not publicly disclosed
What's next for OncoZenge?
The substantial enterprise-level backing positions OncoZenge for accelerated development and potential market entry. This strategic investment is anticipated to fuel further research, clinical trials, and the scaling of operations, bringing their novel pain relief treatment closer to patients in need. The company's trajectory suggests a strong commitment to addressing unmet medical needs within oncology supportive care.
See full OncoZenge company page